DAMP Molecules Enhance Nuclear Reprogramming Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reprogramming somatic cells to induced pluripotent stem cells (iPSCs) face challenges with low efficiency and safety concerns due to genetic modification, particularly with integrating vectors that can cause tumorigenicity and residual foreign DNA, as well as cumbersome non-integrating approaches that reduce reprogramming effectiveness.
Innovation Solution
The use of damage-associated molecular pattern (DAMP) molecules, such as aluminum compositions like aluminum hydroxide, in conjunction with non-integrating reprogramming factors like Oct4, Sox2, Lin28, and Nanog, enhances nuclear reprogramming efficiency by increasing the expression of pluripotency markers and the production of iPSCs, potentially reducing tumorigenic risks and improving method robustness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If DNA-integrating retroviruses and transposons are used for nuclear reprogramming, then reprogramming efficiency is achieved, but tumorigenicity risk and residual foreign DNA increase
Solution Approach 1:
The patent extracts and removes the integrating viral elements (retroviruses and transposons) from the reprogramming system, replacing them with non-integrating methods such as episomal plasmids and mRNA transfection. This eliminates the tumorigenicity risk associated with genomic integration while maintaining reprogramming efficiency through alternative delivery mechanisms.
Solution Approach 2:
The patent introduces intermediary substances including small molecules (valproic acid, trichostatin A) and non-integrating vectors (episomal plasmids, mRNA) that mediate the reprogramming process without requiring viral integration. These intermediaries facilitate chromatin remodeling and gene expression changes necessary for pluripotency induction without the harmful effects of integrating vectors.
2Object-affected harmful factors
If non-integrating vectors are used for reprogramming, then tumorigenicity risk is reduced, but reprogramming efficiency decreases
Solution Approach 1:
The patent employs composite reprogramming systems that combine multiple non-integrating vectors (episomal plasmids containing reprogramming factors) with small molecule additives (valproic acid, trichostatin A). This composite approach compensates for the lower efficiency of individual non-integrating methods by synergistically enhancing reprogramming through both genetic and epigenetic mechanisms.
Solution Approach 2:
The patent optimizes various parameters including the concentration and combination of small molecules (valproic acid, trichostatin A), the design of episomal plasmid vectors, and the timing of reprogramming factor delivery. These parameter changes maximize the efficiency of non-integrating methods while maintaining their safety advantages over integrating vectors.
3Ease of manufacture
If Cre-LoxP site gene delivery or PiggyBac transposon approaches are used, then foreign DNA excision is achieved, but residual foreign DNA remains causing mutagenesis risk
Solution Approach 1:
The patent completely eliminates the need for excision systems like Cre-LoxP or PiggyBac by avoiding integrating vectors altogether. Instead of delivering reprogramming factors through integrative vectors and then requiring their removal, the patent uses non-integrating episomal plasmids and mRNA that naturally remain extrachromosomal and do not require excision, thereby eliminating residual foreign DNA and mutagenesis risk.
4Object-affected harmful factors
If mRNA or episomal DNA plasmids are used for reprogramming, then genetic modification is minimized, but reprogramming efficiency and robustness are reduced
Solution Approach 1:
The patent combines multiple non-integrating reprogramming methods (episomal plasmids, mRNA transfection) with small molecule additives (valproic acid, trichostatin A) to create a composite system. This combination compensates for the inherently lower efficiency of individual non-integrating methods by adding epigenetic modulation that enhances chromatin accessibility and gene expression, thereby improving overall reprogramming robustness without genetic integration.
Solution Approach 2:
The patent optimizes parameters including the design of episomal plasmid vectors (origin of replication, promoter strength), mRNA transfection conditions (concentration, delivery method), and small molecule dosing (valproic acid, trichostatin A concentrations and timing). These optimized parameters maximize the efficiency of non-integrating approaches while maintaining their safety profile.
Data Source
AI summary
Described herein are methods for enhancing the nuclear reprogramming of somatic cells to become induced pluripotent stem cells. In particular, the methods disclosed herein involve the use of damage-associated molecular pattern molecules (DAMP). In certain embodiments the DAMPs are aluminum compositions such as aluminum hydroxide. Such DAMPs have unexpectedly and surprisingly been found to enhance the nuclear reprogramming efficiency of the reprogramming factors commonly used to induce somatic cells to become induced pluripotent stem cells. Accordingly, this disclosure describes methods of nuclear reprogramming as well as cells obtained from such methods along with therapeutic methods for using such cells for the treatment of disease amendable to treatment by stem cell therapy; as well as kits for such uses.